Insights
Insights From Our Experts
Articles
Reimagining Patient Health Experiences: A New Paradigm for Transforming Lives
Traditionally, the healthcare system has approached patient care, especially for those with acute conditions and rare diseases, through a lens of sympathy, problem-solving, and normalization. The focus has often been on identifying deficits and developing tools…
Comparing Long-Term HAE Treatments: Insights from a Robust Network Meta-Analysis
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. While most current treatments can help relieve acute symptoms…
What’s Holding Back AI Transformation?
Takeaways from 2025 Global Digital Transformation Summit Recently, I spoke at the 2025 Global Digital Transformation Summit. The event featured executives from leading companies across the intersection of technology and innovation, and we talked about the…
Navigating the Final FDA SIUU Guidance: Strategic Considerations for Scientific Exchange at ASCO and Other Congresses
Posted by Anne Marie Robertson , Tim Lewis , Susan Giacalone, MSN, BCMAS, MSL-BC on May 29, 20255/29/25
The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue. In this POV, EVERSANA’s Oncology experts…
Most Favored Nation Pricing | Insights and Implications for Manufacturers
The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers. Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing…
Demystifying Market Access: A Must-Read for Navigating the Lab-to-Patient Journey
Market access is no longer just a final hurdle—it’s a strategic imperative that shapes how therapies reach the patients who need them most. If you’ve ever wondered what it really takes to bring a treatment from…
Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower…
EVERSANA Returns as Global Host and Presenting Sponsor for Frontiers Health 2025
Building on its commitment to global health innovation and bringing innovators together from around the globe, EVERSANA returns as the Global Host and Presenting Sponsor of Frontiers Health 2025, which will take place November 11-12 in…
Staying Ahead of the Curve in Pharmacovigilance: CIOMS XIV Draft “Artificial Intelligence in Pharmacovigilance”
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…
Staying Ahead of the Curve in Pharmacovigilance: Outcome of GVP Inspections by NPRA
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…